350 related articles for article (PubMed ID: 22795313)
21. TAK1: Another mesh in the NF-κB - JNK controlled network causing hepatocellular carcinoma.
Greten FR
J Hepatol; 2011 Sep; 55(3):721-723. PubMed ID: 21601601
[TBL] [Abstract][Full Text] [Related]
22. Post-Translational Modifications of the TAK1-TAB Complex.
Hirata Y; Takahashi M; Morishita T; Noguchi T; Matsuzawa A
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106845
[TBL] [Abstract][Full Text] [Related]
23. Receptor proximal kinases in NF-κB signaling as potential therapeutic targets in cancer and inflammation.
Verstrepen L; Beyaert R
Biochem Pharmacol; 2014 Dec; 92(4):519-29. PubMed ID: 25449604
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases.
Fechtner S; Fox DA; Ahmed S
Rheumatology (Oxford); 2017 Jul; 56(7):1060-1068. PubMed ID: 27550296
[TBL] [Abstract][Full Text] [Related]
25. TAK1-TABs Complex: A Central Signalosome in Inflammatory Responses.
Xu YR; Lei CQ
Front Immunol; 2020; 11():608976. PubMed ID: 33469458
[TBL] [Abstract][Full Text] [Related]
26. Reciprocal cross-talk between Nod2 and TAK1 signaling pathways.
Chen CM; Gong Y; Zhang M; Chen JJ
J Biol Chem; 2004 Jun; 279(24):25876-82. PubMed ID: 15075345
[TBL] [Abstract][Full Text] [Related]
27. Suppression of TAK1 pathway by shear stress counteracts the inflammatory endothelial cell phenotype induced by oxidative stress and TGF-β1.
Lee ES; Boldo LS; Fernandez BO; Feelisch M; Harmsen MC
Sci Rep; 2017 Feb; 7():42487. PubMed ID: 28209993
[TBL] [Abstract][Full Text] [Related]
28. Bacterial Nucleotidyl Cyclase Inhibits the Host Innate Immune Response by Suppressing TAK1 Activation.
He C; Zhou Y; Liu F; Liu H; Tan H; Jin S; Wu W; Ge B
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28652310
[TBL] [Abstract][Full Text] [Related]
29. TAK1 control of cell death.
Mihaly SR; Ninomiya-Tsuji J; Morioka S
Cell Death Differ; 2014 Nov; 21(11):1667-76. PubMed ID: 25146924
[TBL] [Abstract][Full Text] [Related]
30. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis.
Safina A; Ren MQ; Vandette E; Bakin AV
Oncogene; 2008 Feb; 27(9):1198-207. PubMed ID: 17828308
[TBL] [Abstract][Full Text] [Related]
31. A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta.
Ono K; Ohtomo T; Ninomiya-Tsuji J; Tsuchiya M
Biochem Biophys Res Commun; 2003 Jul; 307(2):332-7. PubMed ID: 12859960
[TBL] [Abstract][Full Text] [Related]
32. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.
Bettermann K; Vucur M; Haybaeck J; Koppe C; Janssen J; Heymann F; Weber A; Weiskirchen R; Liedtke C; Gassler N; Müller M; de Vos R; Wolf MJ; Boege Y; Seleznik GM; Zeller N; Erny D; Fuchs T; Zoller S; Cairo S; Buendia MA; Prinz M; Akira S; Tacke F; Heikenwalder M; Trautwein C; Luedde T
Cancer Cell; 2010 May; 17(5):481-96. PubMed ID: 20478530
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells.
Thakur N; Sorrentino A; Heldin CH; Landström M
Future Oncol; 2009 Feb; 5(1):1-3. PubMed ID: 19243289
[No Abstract] [Full Text] [Related]
34. Salmonella stimulates pro-inflammatory signalling through p21-activated kinases bypassing innate immune receptors.
Sun H; Kamanova J; Lara-Tejero M; Galán JE
Nat Microbiol; 2018 Oct; 3(10):1122-1130. PubMed ID: 30224799
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function.
Wang Y; Huang G; Vogel P; Neale G; Reizis B; Chi H
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):E343-52. PubMed ID: 22308391
[TBL] [Abstract][Full Text] [Related]
36. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells.
Courties G; Seiffart V; Presumey J; Escriou V; Scherman D; Zwerina J; Ruiz G; Zietara N; Jablonska J; Weiss S; Hoffmann A; Jorgensen C; Apparailly F; Gross G
Blood; 2010 Nov; 116(18):3505-16. PubMed ID: 20682854
[TBL] [Abstract][Full Text] [Related]
37. TAK1 signaling is a potential therapeutic target for pathological angiogenesis.
Zhu L; Lama S; Tu L; Dusting GJ; Wang JH; Liu GS
Angiogenesis; 2021 Aug; 24(3):453-470. PubMed ID: 33973075
[TBL] [Abstract][Full Text] [Related]
38. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling.
Cai PC; Shi L; Liu VW; Tang HW; Liu IJ; Leung TH; Chan KK; Yam JW; Yao KM; Ngan HY; Chan DW
Oncotarget; 2014 Sep; 5(17):7549-62. PubMed ID: 25277189
[TBL] [Abstract][Full Text] [Related]
39. Inducible TAP1 Negatively Regulates the Antiviral Innate Immune Response by Targeting the TAK1 Complex.
Xia Z; Xu G; Yang X; Peng N; Zuo Q; Zhu S; Hao H; Liu S; Zhu Y
J Immunol; 2017 May; 198(9):3690-3704. PubMed ID: 28356387
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
Salazar L; Kashiwada T; Krejci P; Meyer AN; Casale M; Hallowell M; Wilcox WR; Donoghue DJ; Thompson LM
PLoS One; 2014; 9(1):e86470. PubMed ID: 24466111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
